Ozempic and Mounjaro linked to a surprising hair loss risk
A study published in The BMJ suggests a link between GLP-1 receptor agonists, such as Ozempic and Mounjaro, and a modest increase in the risk of hair loss. While the absolute risk remains low, researchers suggest that patients and clinicians should be aware of this potential side effect.
Why it matters
As the use of GLP-1 drugs becomes widespread, identifying and communicating all potential side effects is essential for informed medical decision-making.
GLP-1 medications commonly used to manage type 2 diabetes and obesity may be associated with a modest increase in hair loss, according to a study published by The BMJ on July 22, 2026.
The drug class includes semaglutide, sold under brand names such as Ozempic and Wegovy, and tirzepatide, sold as Mounjaro and Zepbound. Researchers found that adults with type 2 diabetes who used GLP-1 receptor agonists developed alopecia more often than patients taking two other common types of diabetes medication.
Although the relative increase was significant, the researchers emphasized that the absolute risk of hair loss remained low. Still, knowing about the possible side effect could help patients and clinicians make more informed treatment decisions together.
Hair Loss Reports Linked to Ozempic and Similar Drugs
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in